Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Amneal Pharmaceuticals stock

Own Amneal Pharmaceuticals stock in just a few minutes.

Amneal Pharmaceuticals, Inc is a drug manufacturers-specialty & generic business based in the US. Amneal Pharmaceuticals shares (AMRX) are listed on the NYSE and all prices are listed in US Dollars. Amneal Pharmaceuticals employs 6,000 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Amneal Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AMRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Amneal Pharmaceuticals share price

Use our graph to track the performance of AMRX stocks over time.

Amneal Pharmaceuticals shares at a glance

Information last updated 2021-04-30.
52-week range$3.24 - $7.45
50-day moving average $6.28
200-day moving average $5.15
Wall St. target price$6.45
PE ratio 9.1393
Dividend yield N/A (0%)
Earnings per share (TTM) $0.61

Buy Amneal Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Amneal Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Amneal Pharmaceuticals under- or over-valued?

Valuing Amneal Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amneal Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Amneal Pharmaceuticals's P/E ratio

Amneal Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Amneal Pharmaceuticals shares trade at around 9x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Amneal Pharmaceuticals's EBITDA

Amneal Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $381 million.

The EBITDA is a measure of a Amneal Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Amneal Pharmaceuticals financials

Revenue TTM $2 billion
Operating margin TTM 7.31%
Gross profit TTM $652.3 million
Return on assets TTM 2.37%
Return on equity TTM 19.5%
Profit margin 4.57%
Book value $2.05
Market capitalisation $827.5 million

TTM: trailing 12 months

Shorting Amneal Pharmaceuticals shares

There are currently 4.1 million Amneal Pharmaceuticals shares held short by investors – that's known as Amneal Pharmaceuticals's "short interest". This figure is 27% down from 5.6 million last month.

There are a few different ways that this level of interest in shorting Amneal Pharmaceuticals shares can be evaluated.

Amneal Pharmaceuticals's "short interest ratio" (SIR)

Amneal Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Amneal Pharmaceuticals shares currently shorted divided by the average quantity of Amneal Pharmaceuticals shares traded daily (recently around 1.7 million). Amneal Pharmaceuticals's SIR currently stands at 2.47. In other words for every 100,000 Amneal Pharmaceuticals shares traded daily on the market, roughly 2470 shares are currently held short.

However Amneal Pharmaceuticals's short interest can also be evaluated against the total number of Amneal Pharmaceuticals shares, or, against the total number of tradable Amneal Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Amneal Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Amneal Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0414% of the tradable shares (for every 100,000 tradable Amneal Pharmaceuticals shares, roughly 41 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Amneal Pharmaceuticals.

Find out more about how you can short Amneal Pharmaceuticals stock.

Amneal Pharmaceuticals share dividends

We're not expecting Amneal Pharmaceuticals to pay a dividend over the next 12 months.

Amneal Pharmaceuticals share price volatility

Over the last 12 months, Amneal Pharmaceuticals's shares have ranged in value from as little as $3.24 up to $7.445. A popular way to gauge a stock's volatility is its "beta".

AMRX.US volatility(beta: 1.36)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Amneal Pharmaceuticals's is 1.3628. This would suggest that Amneal Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Amneal Pharmaceuticals overview

Amneal Pharmaceuticals, Inc. , together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed, owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinson's disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site